RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Eccogene Biotechnology of Shanghai completed a $14.6 million Series A round led by Sinopharm Capital The company, which was established in January 2018, focuses on new-generation small molecule novel drugs that meet clinical needs at an affordable cost. The company is led by Jingye Zhou, Co-founder and CEO, who previously worked at Lilly and GlaxoSmithKline. Eccogene has established its own drug R&D team, through it plans to use the services of CRO, CMO and clinical research platforms.
Source: China Biotoday
